Hydrochloric Acid → 2-{4-[3-(4,6-Difluoro-1-methyl-1H-indazol-5-ylmethyl)-imidazo[1,2-b]pyridazin-6-yl]-pyrazol-1-yl}-ethanol
반응식
[F:1][C:2]1[C:10]([CH2:11][C:12]2[N:16]3[N:17]=[C:18]([C:21]4[CH:22]=[N:23][N:24]([CH2:26][CH2:27][O:28]C5CCCCO5)[CH:25]=4)[CH:19]=[CH:20][C:15]3=[N:14][CH:13]=2)=[C:9]([F:35])[CH:8]=[C:7]2[C:3]=1[CH:4]=[N:5][N:6]2[CH3:36].Cl.C([O-])(O)=O.[Na+]>O1CCOCC1>[F:1][C:2]1[C:10]([CH2:11][C:12]2[N:16]3[N:17]=[C:18]([C:21]4[CH:22]=[N:23][N:24]([CH2:26][CH2:27][OH:28])[CH:25]=4)[CH:19]=[CH:20][C:15]3=[N:14][CH:13]=2)=[C:9]([F:35])[CH:8]=[C:7]2[C:3]=1[CH:4]=[N:5][N:6]2[CH3:36]참가 물질
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
To a solution of 3-(4,6-difluoro-1-methyl-1H-indazol-5-ylmethyl)-6-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-imidazo[1,2-b]pyridazine (Stage 285.1, 30 mg, 0.061 mmol) in dioxane (2 mL) stirred at 0° C. was added a solution of HCl in dioxane (4 M, 0.152 mL). The RM was stirred 1 h at rt, poured in a solution 10% NaHCO3, and the aqueous phase was extracted with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, hexane/EtOAc=100:0->80:20) to afford the title compound as a white powder (tR 3.68 min (conditions 3), MH+=410.2, 1H-NMR in DMSO-d6: 8.38 (s, 1H); 8.19 (s, 1H); 8.06 (s, 1H); 8.04 (d, 1H); 7.53-7.46 (m, 3H); 4.97 (t, 1H); 4.40 (s, 2H); 4.18 (t, 2H); 3.97 (s, 3H); 3.76 (q, 2H)).
후처리
- extractionthe aqueous phase was extracted with DCM
- dry with materialThe combined organic phases were dried over MgSO4
- concentrationconcentrated under reduced pressure
- customThe residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, hexane/EtOAc=100:0->80:20)
출처 및 근거
- ORD 기록
- ord-963ee83d76b84ab98a1e10dbab706db1
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08822468B2
반응 노트
불러오는 중…